vs
GCI Liberty, Inc.(GLIBA)与Ultragenyx Pharmaceutical Inc.(RARE)财务数据对比。点击上方公司名可切换其他公司
GCI Liberty, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.2倍($257.0M vs $207.3M),Ultragenyx Pharmaceutical Inc.净利率更高(-62.0% vs -150.6%,领先88.6%),GCI Liberty, Inc.自由现金流更多($21.0M vs $-100.8M)
GCI通信公司(GCI Communication Corp)是一家运营于阿拉斯加的电信企业,依托自有基础设施及与其他供应商的合作,向当地客户提供互联网接入、固话及移动电话通讯服务,目前是GCI Liberty, Inc.的全资子公司。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业,专注于研发罕见病和超罕见遗传病的创新治疗方案,这类疾病目前大多无获批疗法,存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台,研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
GLIBA vs RARE — 直观对比
营收规模更大
GLIBA
是对方的1.2倍
$207.3M
净利率更高
RARE
高出88.6%
-150.6%
自由现金流更多
GLIBA
多$121.8M
$-100.8M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $257.0M | $207.3M |
| 净利润 | $-387.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | -189.9% | -54.7% |
| 净利率 | -150.6% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益(稀释后) | $-13.34 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
GLIBA
RARE
| Q4 25 | — | $207.3M | ||
| Q3 25 | $257.0M | $159.9M | ||
| Q2 25 | $261.0M | $166.5M | ||
| Q1 25 | — | $139.3M | ||
| Q4 24 | — | $164.6M | ||
| Q3 24 | — | $139.5M | ||
| Q2 24 | — | $147.0M | ||
| Q1 24 | — | $108.8M |
净利润
GLIBA
RARE
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $-387.0M | $-180.4M | ||
| Q2 25 | $27.0M | $-115.0M | ||
| Q1 25 | — | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | — | $-133.5M | ||
| Q2 24 | — | $-131.6M | ||
| Q1 24 | — | $-170.7M |
营业利润率
GLIBA
RARE
| Q4 25 | — | -54.7% | ||
| Q3 25 | -189.9% | -106.9% | ||
| Q2 25 | 19.5% | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | — | -94.6% | ||
| Q2 24 | — | -79.1% | ||
| Q1 24 | — | -151.9% |
净利率
GLIBA
RARE
| Q4 25 | — | -62.0% | ||
| Q3 25 | -150.6% | -112.8% | ||
| Q2 25 | 10.3% | -69.0% | ||
| Q1 25 | — | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | — | -95.7% | ||
| Q2 24 | — | -89.5% | ||
| Q1 24 | — | -156.8% |
每股收益(稀释后)
GLIBA
RARE
| Q4 25 | — | $-1.28 | ||
| Q3 25 | $-13.34 | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $124.0M | $421.0M |
| 总债务越低越好 | $985.0M | — |
| 股东权益账面价值 | $1.4B | $-80.0M |
| 总资产 | $3.0B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.72× | — |
8季度趋势,按日历期对齐
现金及短期投资
GLIBA
RARE
| Q4 25 | — | $421.0M | ||
| Q3 25 | $124.0M | $202.5M | ||
| Q2 25 | $104.0M | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
总债务
GLIBA
RARE
| Q4 25 | — | — | ||
| Q3 25 | $985.0M | — | ||
| Q2 25 | $987.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益
GLIBA
RARE
| Q4 25 | — | $-80.0M | ||
| Q3 25 | $1.4B | $9.2M | ||
| Q2 25 | — | $151.3M | ||
| Q1 25 | — | $144.2M | ||
| Q4 24 | — | $255.0M | ||
| Q3 24 | — | $346.8M | ||
| Q2 24 | — | $432.4M | ||
| Q1 24 | — | $140.3M |
总资产
GLIBA
RARE
| Q4 25 | — | $1.5B | ||
| Q3 25 | $3.0B | $1.2B | ||
| Q2 25 | $3.4B | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.3B |
负债/权益比
GLIBA
RARE
| Q4 25 | — | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $76.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $21.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 8.2% | -48.6% |
| 资本支出强度资本支出/营收 | 21.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势,按日历期对齐
经营现金流
GLIBA
RARE
| Q4 25 | — | $-99.8M | ||
| Q3 25 | $76.0M | $-91.4M | ||
| Q2 25 | $226.0M | $-108.3M | ||
| Q1 25 | — | $-166.5M | ||
| Q4 24 | — | $-79.3M | ||
| Q3 24 | — | $-67.0M | ||
| Q2 24 | — | $-77.0M | ||
| Q1 24 | — | $-190.7M |
自由现金流
GLIBA
RARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | $21.0M | $-92.7M | ||
| Q2 25 | $107.0M | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率
GLIBA
RARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | 8.2% | -58.0% | ||
| Q2 25 | 41.0% | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度
GLIBA
RARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | 21.4% | 0.8% | ||
| Q2 25 | 45.6% | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
现金转化率
GLIBA
RARE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 8.37× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GLIBA
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |